Search Results - krishna

2 Results Sort By:
T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy
Summary: The NCI seeks parties interested in research co-development and/or licensing this library of TCRs targeting CDKN2A mutations. Description of Technology: Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s): Sri Krishna, Shoshana Levi, Paul Robbins, Steven Rosenberg, Shirley Nah, Rami Yoseph, Frank Lowery
Keywords(s): adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer
Summary: The NCI seeks parties interested in research co-development and/or licensing of this combination immunotherapy approach of neoantigen-specific T cells administered alongside a neoantigen-targeting vaccine to enhance ACT and treat cancer. Description of Technology: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s): Sri Krishna, Zhiya Yu, Kenichi Hanada, Steven Rosenberg
Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Krishna, Neoantigen, Rosenberg, T-Cell Receptor, TCR, Vaccine
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics